An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index

ZS Wallace, A Khosroshahi, MD Carruthers, CA Perugino, H Choi, C Campochiaro, EL Culver, F Cortazar, E Della-torre, M Ebbo, A Fernandes, L Frulloni, PA Hart, O Karadag, S Kawa, M Kawano, MH Kim, M Lanzillotta, S Matsui, K Okazaki & 8 others JH Ryu, T Saeki, N Schleinitz, P Tanasa, H Umehara, G Webster, W Zhang, JH Stone

Research output: Contribution to journalArticle

Abstract

Objective: IgG4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ, leading to organ dysfunction and failure. The IgG4-RD Responder Index (RI) was developed to help investigators assess the efficacy of treatment in a structured manner. The aim of this study was to validate the RI in a multinational investigation. Methods: The RI guides investigators through assessments of disease activity and damage in 25 domains, incorporating higher weights for disease manifestations that require urgent treatment or that worsen despite treatment. After a training exercise, investigators reviewed 12 written IgG4-RD vignettes based on real patients. Investigators calculated both an RI score as well as a physician's global assessment (PhGA) score for each vignette. In a longitudinal assessment, 3 investigators used the RI in 15 patients with newly active disease who were followed up over serial visits after treatment. We assessed interrater and intrarater reliability, precision, validity, and responsiveness. Results: The 26 physician investigators included representatives from 6 specialties and 9 countries. The interrater and intrarater reliability of the RI was strong (0.89 and 0.69, respectively). Correlations (construct validity) between the RI and PhGA were high (Spearman's r = 0.9, P <0.0001). The RI was sensitive to change (discriminant validity). Following treatment, there was significant improvement in the RI score (mean change 10.5 [95% confidence interval (95% CI) 5.4–12], P <0.001), which correlated with the change in the PhGA. Urgent disease and damage were captured effectively. Discussion: In this international, multispecialty study, we observed that the RI is a valid and reliable disease activity assessment tool that can be used to measure response to therapy. © 2018, American College of Rheumatology
Original languageEnglish
Pages (from-to)1671-1678
Number of pages8
JournalArthritis Care and Research
Volume70
Issue number11
DOIs
Publication statusPublished - 2018

Fingerprint

Validation Studies
Immunoglobulin G
Research Personnel
Physicians
Therapeutics
Reproducibility of Results
Confidence Intervals
Exercise
Weights and Measures

Cite this

Wallace, ZS., Khosroshahi, A., Carruthers, MD., Perugino, CA., Choi, H., Campochiaro, C., ... Stone, JH. (2018). An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index. Arthritis Care and Research, 70(11), 1671-1678. https://doi.org/10.1002/acr.23543

An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index. / Wallace, ZS; Khosroshahi, A; Carruthers, MD; Perugino, CA; Choi, H; Campochiaro, C; Culver, EL; Cortazar, F; Della-torre, E; Ebbo, M; Fernandes, A; Frulloni, L; Hart, PA; Karadag, O; Kawa, S; Kawano, M; Kim, MH; Lanzillotta, M; Matsui, S; Okazaki, K; Ryu, JH; Saeki, T; Schleinitz, N; Tanasa, P; Umehara, H; Webster, G; Zhang, W; Stone, JH.

In: Arthritis Care and Research, Vol. 70, No. 11, 2018, p. 1671-1678.

Research output: Contribution to journalArticle

Wallace, ZS, Khosroshahi, A, Carruthers, MD, Perugino, CA, Choi, H, Campochiaro, C, Culver, EL, Cortazar, F, Della-torre, E, Ebbo, M, Fernandes, A, Frulloni, L, Hart, PA, Karadag, O, Kawa, S, Kawano, M, Kim, MH, Lanzillotta, M, Matsui, S, Okazaki, K, Ryu, JH, Saeki, T, Schleinitz, N, Tanasa, P, Umehara, H, Webster, G, Zhang, W & Stone, JH 2018, 'An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index', Arthritis Care and Research, vol. 70, no. 11, pp. 1671-1678. https://doi.org/10.1002/acr.23543
Wallace ZS, Khosroshahi A, Carruthers MD, Perugino CA, Choi H, Campochiaro C et al. An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index. Arthritis Care and Research. 2018;70(11):1671-1678. https://doi.org/10.1002/acr.23543
Wallace, ZS ; Khosroshahi, A ; Carruthers, MD ; Perugino, CA ; Choi, H ; Campochiaro, C ; Culver, EL ; Cortazar, F ; Della-torre, E ; Ebbo, M ; Fernandes, A ; Frulloni, L ; Hart, PA ; Karadag, O ; Kawa, S ; Kawano, M ; Kim, MH ; Lanzillotta, M ; Matsui, S ; Okazaki, K ; Ryu, JH ; Saeki, T ; Schleinitz, N ; Tanasa, P ; Umehara, H ; Webster, G ; Zhang, W ; Stone, JH. / An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index. In: Arthritis Care and Research. 2018 ; Vol. 70, No. 11. pp. 1671-1678.
@article{f7c73861bb504f1e9aa4ce018736867f,
title = "An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index",
abstract = "Objective: IgG4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ, leading to organ dysfunction and failure. The IgG4-RD Responder Index (RI) was developed to help investigators assess the efficacy of treatment in a structured manner. The aim of this study was to validate the RI in a multinational investigation. Methods: The RI guides investigators through assessments of disease activity and damage in 25 domains, incorporating higher weights for disease manifestations that require urgent treatment or that worsen despite treatment. After a training exercise, investigators reviewed 12 written IgG4-RD vignettes based on real patients. Investigators calculated both an RI score as well as a physician's global assessment (PhGA) score for each vignette. In a longitudinal assessment, 3 investigators used the RI in 15 patients with newly active disease who were followed up over serial visits after treatment. We assessed interrater and intrarater reliability, precision, validity, and responsiveness. Results: The 26 physician investigators included representatives from 6 specialties and 9 countries. The interrater and intrarater reliability of the RI was strong (0.89 and 0.69, respectively). Correlations (construct validity) between the RI and PhGA were high (Spearman's r = 0.9, P <0.0001). The RI was sensitive to change (discriminant validity). Following treatment, there was significant improvement in the RI score (mean change 10.5 [95{\%} confidence interval (95{\%} CI) 5.4–12], P <0.001), which correlated with the change in the PhGA. Urgent disease and damage were captured effectively. Discussion: In this international, multispecialty study, we observed that the RI is a valid and reliable disease activity assessment tool that can be used to measure response to therapy. {\circledC} 2018, American College of Rheumatology",
author = "ZS Wallace and A Khosroshahi and MD Carruthers and CA Perugino and H Choi and C Campochiaro and EL Culver and F Cortazar and E Della-torre and M Ebbo and A Fernandes and L Frulloni and PA Hart and O Karadag and S Kawa and M Kawano and MH Kim and M Lanzillotta and S Matsui and K Okazaki and JH Ryu and T Saeki and N Schleinitz and P Tanasa and H Umehara and G Webster and W Zhang and JH Stone",
year = "2018",
doi = "10.1002/acr.23543",
language = "English",
volume = "70",
pages = "1671--1678",
journal = "Arthritis care and research : the official journal of the Arthritis Health Professions Association",
issn = "0893-7524",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index

AU - Wallace, ZS

AU - Khosroshahi, A

AU - Carruthers, MD

AU - Perugino, CA

AU - Choi, H

AU - Campochiaro, C

AU - Culver, EL

AU - Cortazar, F

AU - Della-torre, E

AU - Ebbo, M

AU - Fernandes, A

AU - Frulloni, L

AU - Hart, PA

AU - Karadag, O

AU - Kawa, S

AU - Kawano, M

AU - Kim, MH

AU - Lanzillotta, M

AU - Matsui, S

AU - Okazaki, K

AU - Ryu, JH

AU - Saeki, T

AU - Schleinitz, N

AU - Tanasa, P

AU - Umehara, H

AU - Webster, G

AU - Zhang, W

AU - Stone, JH

PY - 2018

Y1 - 2018

N2 - Objective: IgG4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ, leading to organ dysfunction and failure. The IgG4-RD Responder Index (RI) was developed to help investigators assess the efficacy of treatment in a structured manner. The aim of this study was to validate the RI in a multinational investigation. Methods: The RI guides investigators through assessments of disease activity and damage in 25 domains, incorporating higher weights for disease manifestations that require urgent treatment or that worsen despite treatment. After a training exercise, investigators reviewed 12 written IgG4-RD vignettes based on real patients. Investigators calculated both an RI score as well as a physician's global assessment (PhGA) score for each vignette. In a longitudinal assessment, 3 investigators used the RI in 15 patients with newly active disease who were followed up over serial visits after treatment. We assessed interrater and intrarater reliability, precision, validity, and responsiveness. Results: The 26 physician investigators included representatives from 6 specialties and 9 countries. The interrater and intrarater reliability of the RI was strong (0.89 and 0.69, respectively). Correlations (construct validity) between the RI and PhGA were high (Spearman's r = 0.9, P <0.0001). The RI was sensitive to change (discriminant validity). Following treatment, there was significant improvement in the RI score (mean change 10.5 [95% confidence interval (95% CI) 5.4–12], P <0.001), which correlated with the change in the PhGA. Urgent disease and damage were captured effectively. Discussion: In this international, multispecialty study, we observed that the RI is a valid and reliable disease activity assessment tool that can be used to measure response to therapy. © 2018, American College of Rheumatology

AB - Objective: IgG4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ, leading to organ dysfunction and failure. The IgG4-RD Responder Index (RI) was developed to help investigators assess the efficacy of treatment in a structured manner. The aim of this study was to validate the RI in a multinational investigation. Methods: The RI guides investigators through assessments of disease activity and damage in 25 domains, incorporating higher weights for disease manifestations that require urgent treatment or that worsen despite treatment. After a training exercise, investigators reviewed 12 written IgG4-RD vignettes based on real patients. Investigators calculated both an RI score as well as a physician's global assessment (PhGA) score for each vignette. In a longitudinal assessment, 3 investigators used the RI in 15 patients with newly active disease who were followed up over serial visits after treatment. We assessed interrater and intrarater reliability, precision, validity, and responsiveness. Results: The 26 physician investigators included representatives from 6 specialties and 9 countries. The interrater and intrarater reliability of the RI was strong (0.89 and 0.69, respectively). Correlations (construct validity) between the RI and PhGA were high (Spearman's r = 0.9, P <0.0001). The RI was sensitive to change (discriminant validity). Following treatment, there was significant improvement in the RI score (mean change 10.5 [95% confidence interval (95% CI) 5.4–12], P <0.001), which correlated with the change in the PhGA. Urgent disease and damage were captured effectively. Discussion: In this international, multispecialty study, we observed that the RI is a valid and reliable disease activity assessment tool that can be used to measure response to therapy. © 2018, American College of Rheumatology

U2 - 10.1002/acr.23543

DO - 10.1002/acr.23543

M3 - Article

VL - 70

SP - 1671

EP - 1678

JO - Arthritis care and research : the official journal of the Arthritis Health Professions Association

JF - Arthritis care and research : the official journal of the Arthritis Health Professions Association

SN - 0893-7524

IS - 11

ER -